SC144@HABN + anti-PD-L1 combo therapy exerted potent anti-tumor efficacy, as shown by significantly reduced tumor growth, compared with SC144 + anti-PD-L1 or anti-PD-L1 monotherapy (p < 0.0001) as well as SC144@HABN monotherapy (p < 0.01) (Fig. 5e). Here, CD274 is linked to neoplasm.